Ironwood Pharmaceuticals, Inc. (IRWD) stock saw a modest uptick, ending the day at $4.51 which represents a slight increase of $0.18 or 4.16% from the prior close of $4.33. The stock opened at $4.33 ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.61% ...

Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a ...

Fintel reports that on December 12, 2024, Leerink Partners downgraded their outlook for LAVA Therapeutics N.V. (NasdaqGS:LVTX ...

After Axsome Therapeutics (AXSM) reported that its ACCORD-2 trial in Alzheimer’s disease agitation met its the primary endpoint, but that the ...

(Bloomberg) -- Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from boutiques Guggenheim Securities and Gordon Dyal & Co., people with ...

Wells Fargo & Co. has hired health-care banker Michael Giaquinto as a managing director focused on the medical technology ...

Leerink lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $6 from $8 and keeps an Outperform rating on the shares after the ...

Stock analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for Walgreens Boots Alliance in a ...

Leerink analyst Daina Graybosch downgraded Lava Therapeutics (LVTX) to Market Perform from Outperform with a price target of $2, down from $11, following the company’s discontinuation of LAVA ...

https://www.tipranks.com/news/the-fly/iteos-therapeutics-price-target-lowered-to-19-from-31-at-wells-fargo Leerink analyst Christopher Liu lowered the firm’s price ...

Leerink analyst Daniel Clark initiated coverage of Elanco (ELAN) with a Market Perform rating and $14 price target The firm notes Elanco trades at the most attractive multiple in the animal health ...